<DOC>
	<DOC>NCT01120769</DOC>
	<brief_summary>The purpose of this study is to test the hypothesis that acetaminophen will reduce lipid peroxidation and isoprostane formation during reperfusion after percutaneous revascularization for acute myocardial infarction.</brief_summary>
	<brief_title>Acetaminophen to Prevent Ischemic Oxidative Reperfusion Injury During Percutaneous Coronary Intervention for Acute Myocardial Infarction</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Reperfusion Injury</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Patients presenting with STEMI Duration of symptoms &gt; 12 hours Suspected LM or proximal LAD occlusion (based on EKG interpretation) Hemodynamic instability Acetaminophen use in prior 24 hours Use of dipyridamole, or Aggrenox, a formulation of aspirin and extendedrelease dipyridamole, within 48 hours Current use of the following medications: phenytoin, valproic acid, phenobarbital, topiramate, rifampin, carbamazepine, cyclophosphamide, ritonavir, efavirenz, St. John's Wort Chronic heavy alcohol use Chronic liver disease (other than nonalcoholic fatty liver infiltration) Severe valvular heart disease Stroke in the past 60 days Active major bleeding Major surgery in the past 30 days Ongoing treatment for active malignancy Life expectancy less than 12 months as determined by the patient's attending physician Pregnancy asthma or severe COPD active wheezing on presentation allergy or prior adverse reaction to adenosine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Myocardial Infarction</keyword>
	<keyword>Percutaneous Coronary Intervention</keyword>
	<keyword>Acetaminophen</keyword>
	<keyword>Lipid Peroxidation</keyword>
</DOC>